Identification of DNA differential methylation markers in breast tumors with different response to neoadjuvant chemotherapy

Abstract

Breast cancer (BC) occupies a leading position among neoplasms in women in terms of morbidity and mortality. Despite the advantages of neoadjuvant chemotherapy (NACT) which allows achieving high treatment results, a significant part of patients with residual tumor and significantly worse prognosis remains. We have carried out a genome-wide DNA methylation analysis and identified 33 genes methylation of which distinguishes breast tumors with different responses to NACT. Our findings provide the basis for development of test systems for diagnostics of potential sensitivity of breast tumors to NACT via DNA methylation analysis.